Roy Blum, Ph.D.

Laura and Isaac Perlmutter Cancer Center, Department of Pathology,

New York University Langone School of Medicine

*** ***** ******, *** ****, NY 10016

Mobile: 646-***-****; e-mail: acep74@r.postjobfree.com

Website: http://sites.google.com/site/blumroy

USA Permanent Resident (Greencard holder); EU and Israeli citizenships

CAREER OBJECTIVE

A medical writing position in the medical writing industry

QUALIFICATION SUMMARY

Summa Cum Laude Ph.D in Neurobiochemistry with 14 years of experience in researching, analyzing and

writing scientific manuscripts, review articles, posters, presentations, abstracts, grant proposals, rebuttal letters,

experimental protocols and slide kits.

Scientific expertise in oncology therapeutics (prostate tumor and glioblastoma), combinatorial drug therapy, stem

cells, muscle disorders and pediatric leukemia.

13 first-author and 5 contributing-author peer-reviewed articles in prestigious journals, including Mol. Cell,

Genes & Development and PNAS.

5 first-author peer-reviewed review articles on drug development, cancer therapeutics, metabolism and muscle

development – published in prestigious journals, including Cell Death & Disease and J Cell Biochem.

Excellent writing, editing and research skills. Extensively experienced in formal written and oral presentation of

research projects and medical/scientific educational material for a variety of audiences. Excellent analytical

thinking skills and a keen ability to multi-task. Detail oriented.

Invited speaker and presenter at national and international conferences.

Outstanding expertise with literature repositories and searching tools such as PubMed, Medline, OVID, NCBI,

NLM, etc.

Excellent proficiency with Microsoft Office tools (Word, Excel and PowerPoint) and with citati on management

softwares as EndNote (a former computer programmer in C/C++, Perl, Matlab, Python and others).

OCCUPATIONAL EXPERIENCE and POSTGRADUATE RESEARCH

2007 – Present

New York University School of Medicine, New York, NY

2008 – 2013

Senior Research Scientist (Molecular Genomics),

Laura and Issac Perlmutter Cancer Center, New York University Langone School of Medicine

Project: Epigenetic mechanisms leading to relapse of pediatric Acute Lymphoblastic Leukemia

Published three solicited peer-reviewed review articles in Epigenetics, Cell Death & Disease and J Cell Biochem

(see Appendix).

Developed, wrote and submitted a K99 grant proposal to the NIH.

1

2008 – 2013

Post-Doctoral Fellow (Molecular Genomics), Department of Pathology

Principal Investigator: Brian Dynlacht, Ph.D., Molecular genetics training program sponsored by the NIH

Project: Studies on muscle development with significant implications for obesity, atrophy and muscle disorders

Synthesized and concisely summarized my research into two first-author peer-reviewed articles published in

Genes & Development and PNAS (see Appendix).

Developed and wrote a grant proposal to support my research.

Lectured to the Pathology department on my research discoveries.

2007 – 2008

Post-Doctoral Fellow (Stem Cell Biology), Department of Cell Biology

Principal Investigator: Elaine L. Wilson, Ph.D., Stem cell training program sponsored by the NIH

Project: Studies on the molecular signature of prostate stem cells, with implications for prostate cancer

Synthesized and concisely summarized my research into two first-author peer-reviewed articles published in

PlosONE (see Appendix).

Developed and wrote an NIH grant proposal and progress reports to support my research.

Lectured to the Cell Biology department on my research discoveries.

Led a team of three researchers to perform microarray analysis of adult and embryonic murine prostat e stem

cells.

TEACHING AND MANAGERIAL EXPERIENCE

2006 – 2007

Consultant, Bioinformatics Unit of Tel Aviv University, Israel

Guided students and faculty members on methods of executing computational tasks.

Mentored and supervised new team members and undergraduate rotation students.

Lectured on the potential of analysis software as a research tool.

EDUCATION

1997 – 2007

Tel Aviv University, Faculty of Life Sciences, Tel Aviv, Israel

Ph.D, Neurobiochemistry (Summa Cum Laude)

2002 – 2007

Principal Investigator: Yoel Kloog, Ph.D., Department of Neurobiochemistry

Dissertation: Studies on the mechanism of action of the proto-oncogene Ras in human glioblastoma: New

approaches to brain tumor therapy utilizing the Ras inhibitor salirasib.

Synthesized and concisely summarized my research into four first-author and one contributing-author peer-

reviewed journal articles.

Initiated the research and writing of two first-author review articles on drug discovery and cancer therapeutics

(see Appendix).

Developed and wrote a few grant proposals and progress reports to support my research.

Analytically developed, structured, researched and wrote doctoral dissertation in the field of drug development

and cancer therapeutics. My dissertation was honored Summa Cum Laude.

Synthesized and concisely summarized my research in abstracts for poster presentation in several scientific

meetings (see Appendix).

Lectured on my doctoral discoveries in faculty seminars, scientific meetings and international conferences (see

Appendix).

2

2000 – 2001

M.Sc. in Neurobiochemistry (Summa Cum Laude)

Principal Investigator: Yoel Kloog, Ph.D., Department of Neurobiochemistry

1997 – 1999

B.Sc. in Biology and Life Sciences (Summa Cum Laude)

HONORS AND AWARDS

Dan David scholarship award for contribution in the field of cancer therapy – 2006, Tel Aviv, Israel

Rector award – 2004, Tel Aviv University, Israel

Dean award for excellence – 2003, Tel Aviv University, Israel

3

APPENDIX

SEMINAR GIVEN (selected list)

Dept. of Cell Biology, NYU, Lecture: “Transcriptional characterization of prostate stem cells”. Jul 2008

Memorial Sloan-Kettering, NYC, Lecture: “Biochemical and gene expression analysis of GBM cells treated with

the Ras inhibitor salirasib”. Sep 2006

International meeting on whole genome studies and the power of microarrays, Sheba Medical Center, Israel,

Lecture: “Gene expression analysis of GBM cells treated with FTS”. Feb 2006

Lecture and lesson in course: ”Analysis of Microarray Data Using the EXPANDER and SHARP Tools”, School

of Computer Science, Tel Aviv University, Israel. Jan 2006

4th Tuscany Retreat on Cancer, Tuscany, Italy. Lecture: “Ras Inhibitors and Malignant Glioma”. Aug 2005

4th Federation of Israel Societies for Experimental Biology Congress, Eilat, Israel. Poster: “Ras inhibition in

GBM down-regulates HIF-1a, causing glycolysis shutdown and cell death”. Feb 2005

Cancer Biology Research Center Annual Meeting, Kfar Blum, Israel. Lecture: “Ras inhibitors and malignant

glioma”. Apr 2004

3rd Federation of Israel Societies for Experimental Biology Congress, Eilat, Israel. Poster: “Galectin -3 is a

binding partner of oncogenic K-Ras”. Feb 2002

PEER-REVIEWED PUBLICATIONS WRITTEN

1. Vitanza NA, Zaky W, Blum R, Meyer JA, Wang J, Bhatla T, Morrison DJ, Raetz EA, Carroll WL. 2014. Ikaros

deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene

expression signature but do not result in intrinsic chemoresistance. Pediatr Blood Cancer. [accepted for

publication].

2. Blum R. 2014. Activation of muscle enhancers by MyoD and epigenetic modifiers. J Cell Biochem. Jun 6. doi :

10.1002/jcb.24854. [Epub ahead of print]. (solicited review article on myogenic enhancers).

3. Jones CL, Bhatla T, Blum R, Wang J, Paugh SW, Wen X, Bourgeois W, Bitterman DS, Raetz EA, Morrison

DJ, Teachey DT, Evans WE, Garabedian MJ and Carroll WL. Loss of TBL1XR1 Disrupts glucocorticoid

receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model.

J Biol Chem. Jun 3. pii: jbc.M114.569889. [Epub ahead of print]

4. Cheng J, Blum R, Bowman C, Shilatifard A, Dynlacht BD. 2014. A role for H3K4 mono-methylation in

facultative heterochromatin assembly and partitioning chromatin readers. Mol. Cell. 53(6):979-92.

5. Blum R, Kloog Y. 2014. Metabolism addiction in pancreatic cancer. Cell Death & Disease. 5:e1065. (Solicited

review article).

6. Blum R, Dynlacht BD. 2013. The role of MyoD1 and histone modifications in the activation of muscle

enhancers. Epigenetics. 8(8): 778-784. (solicited review article on myogenic enhancers).

7. Blum R, Vethantham V, Bowman C, Rudnicki M and Dynlacht BD. 2012. Genome-wide identification of

enhancers in skeletal muscle: The role of MyoD1. Genes Dev. 26(24):2763-2779.

8. Vazquez-Cintron EJ, Monu NR, Burns JC, Blum R, Chen G, Lopez P, Ma J, Radoja S, Frey AB. 2012.

Protocadherin-18 is a novel differentiation marker and an Inhibitory signaling receptor for CD8+ effector

memory T cells. PLoS ONE. 7(5):e36101.

9. Asp P*, Blum R*, Vethantham V, Parisi F, Micsinai M, Cheng J, Bowman C, Kluger Y, Dynlacht BD. 2011.

Genome-wide remodeling of the epigenetic landscape during myogenic differentiation. Proc Natl Acad Sci

USA. 108(22):E149-58. (*Equal first authorship).

10. Blum R, Gupta R, Burger PE, Ontiveros CS, Salm SN, Xiong X, Kamb A, Wesche H, Marshall L, Cutler G,

Wang X, Zavadil J, Moscatelli D, Wilson EL. Molecular signatures of urogenital sinus epithelium and

urogenital sinus mesenchyme reveal noval signaling pathways and ligand -receptor interactions in the primitive

prostate stem cell niche. PLoS ONE. 2010;5(9):e13024.

4

11. Blum R, Gupta R, Burger PE, Ontiveros CS, Salm SN, Xiong X, Kamb A, Wesche H, Marshall L, Cutler G,

Wang X, Zavadil J, Moscatelli D, Wilson EL. Molecular signatures of prostate stem cells reveal novel signaling

pathways and provide insights into prostate cancar. PLoS ONE. 2009;4(5):e5722

12. Blum R, Cox AD, Kloog Y. Inhibitors of chronically active Ras: potential for treatment of human

malignancies. Recent Patents on Anti-Cancer Drug Discovery. 2008 Jan 1;3(17): 31-47 (an invited review

article on selective oncogenic inhibitors for cancer therapy)

13. Blum R, Elkon R, Yaari S, Zundelevich A, Jacob-Hirsch J, Rechavi G, Shamir R, Kloog Y. Gene expression

signature of human cancer cell lines treated with the Ras inhibitor salirasib (FTS). Cancer Res. 2007 Apr

1;67(7):3320-33281 (conspicuous research on the principal mechanism of action of FTS)

14. Erlich S, Tal-Or P, Blum R, Kloog Y, Pinkas-Kramarski R. Ras inhibition results in growth arrest and death of

androgen-dependent and androgen-independent prostate cancer cells. Biochem Pharmacol. 2006 Aug

14;72(4):427-36

15. Blum R and Kloog Y. Tailoring Ras-pathway – inhibitor combinations for cancer therapy. Drug Resist Updat.

2005 Dec 12;8(6):369-380 (an invited review article on targeted combinatorial therapy)

16. Blum R, Jacob-Hirsch J, Rechavi G, Kloog Y. Suppression of survi vin expression in glioblastoma by the Ras

inhibitor trans-farnesylthiosalicylic acid (FTS) promotes caspase-dependent apoptosis. Mol Cancer Ther. 2006

Sept;5(9):2337-47

17. Blum R, Nakdimon I, Goldberg L, Elkon R, Shamir R, Rechavi G, Kloog Y. E2F1 identified by promoter and

biochemical analysis as a central target of glioblastoma cell -cycle arrest in response to Ras inhibition. Int. J.

Cancer 2006 Feb 22;119(3), 527–538

18. Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G, Kloog Y. Ras inhibition in glioblastoma do wn-regulates

hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res. 2005 Feb

1;65(3):999-1006 (a highly cited research that demonstrates the tight connection between Ras and HIF1a)

5

Contact this candidate